Literature DB >> 1376328

Induction of active and adoptive relapsing experimental autoimmune encephalomyelitis (EAE) using an encephalitogenic epitope of proteolipid protein.

B L McRae1, M K Kennedy, L J Tan, M C Dal Canto, K S Picha, S D Miller.   

Abstract

Proteolipid protein (PLP) is a major component of the central nervous system (CNS) myelin membrane and has been shown to induce acute experimental autoimmune encephalomyelitis (EAE) in genetically susceptible animals. Here we describe conditions by which a relapsing-remitting form of EAE can be reliably induced in SJL/J mice either actively immunized with the major encephalitogenic PLP peptide, PLP13-151(S), or following adoptive transfer of PLP139-151(S)-specific T cells. The disease follows a reliable relapsing-remitting course with acute clinical signs first appearing 6-20 days after priming or transfer and relapses first appearing at 30-45 days. The initial onset of disease correlates with delayed-type hypersensitivity (DTH) reactivity specific for PLP139-151(S), in the apparent absence of T cell reactivity to the major myelin basic protein (MBP) peptide. Histologically, both the active and adoptive forms of the disease are characterized by extensive mononuclear cell infiltration and severe demyelination of the CNS. These results suggest that T cell responses specific for PLP139-151(S) are sufficient to induce clinical and histological R-EAE in SJL/J mice. This model should prove useful for examination of the cellular and molecular events involved in clinical relapses and perhaps in determining the role of PLP-specific T cell responses in multiple sclerosis (MS).

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1376328     DOI: 10.1016/0165-5728(92)90016-e

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  54 in total

1.  Normal Th1 development following long-term therapeutic blockade of CD154-CD40 in experimental autoimmune encephalomyelitis.

Authors:  Laurence M Howard; Serge Ostrovidov; Cassandra E Smith; Mauro C Dal Canto; Stephen D Miller
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

Review 2.  The origin and regulation of autopathogenic T cells.

Authors:  A C Anderson; L B Nicholson; V K Kuchroo
Journal:  J Clin Immunol       Date:  2001-03       Impact factor: 8.317

3.  The tick saliva immunosuppressor, Salp15, contributes to Th17-induced pathology during Experimental Autoimmune Encephalomyelitis.

Authors:  Ignacio J Juncadella; Tonya C Bates; Reem Suleiman; Andrea Monteagudo-Mera; Chris M Olson; Nicolás Navasa; Elias R Olivera; Barbara A Osborne; Juan Anguita
Journal:  Biochem Biophys Res Commun       Date:  2010-11-05       Impact factor: 3.575

Review 4.  Mechanisms regulating regional localization of inflammation during CNS autoimmunity.

Authors:  Emily Pierson; Sarah B Simmons; Luca Castelli; Joan M Goverman
Journal:  Immunol Rev       Date:  2012-07       Impact factor: 12.988

5.  Substrain differences reveal novel disease-modifying gene candidates that alter the clinical course of a rodent model of multiple sclerosis.

Authors:  Leslie E Summers deLuca; Natalia B Pikor; Jennifer O'Leary; Georgina Galicia-Rosas; Lesley A Ward; Dustin Defreitas; Trisha M Finlay; Shalina S Ousman; Lucy R Osborne; Jennifer L Gommerman
Journal:  J Immunol       Date:  2010-02-19       Impact factor: 5.422

6.  Multi-peptide coupled-cell tolerance ameliorates ongoing relapsing EAE associated with multiple pathogenic autoreactivities.

Authors:  Cassandra E Smith; Stephen D Miller
Journal:  J Autoimmun       Date:  2006-12       Impact factor: 7.094

7.  Enhancing the ability of experimental autoimmune encephalomyelitis to serve as a more rigorous model of multiple sclerosis through refinement of the experimental design.

Authors:  Mitchell R Emerson; Ryan J Gallagher; Janet G Marquis; Steven M LeVine
Journal:  Comp Med       Date:  2009-04       Impact factor: 0.982

Review 8.  Mouse models of neurological disorders: a view from the blood-brain barrier.

Authors:  William A Banks
Journal:  Biochim Biophys Acta       Date:  2009-10-29

Review 9.  A gene therapy approach to treatment of autoimmune disease.

Authors:  C M Seroogy; C G Fathman
Journal:  Immunol Res       Date:  1998-08       Impact factor: 2.829

10.  IL-11 antagonist suppresses Th17 cell-mediated neuroinflammation and demyelination in a mouse model of relapsing-remitting multiple sclerosis.

Authors:  Xin Zhang; Nazanin Kiapour; Sahil Kapoor; Joseph R Merrill; Yongjuan Xia; Woomi Ban; Stephanie M Cohen; Bentley R Midkiff; Valerie Jewells; Yen-Yu I Shih; Silva Markovic-Plese
Journal:  Clin Immunol       Date:  2018-08-24       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.